Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
Eur J Heart Fail. 2022 Jul;24(7):1293-1301. doi: 10.1002/ejhf.2467. Epub 2022 Mar 21.
Tricuspid regurgitation (TR) is associated with high mortality, morbidity and reduced physical capacity. This study was designed to examine the long-term impact of transcatheter tricuspid valve intervention (TTVI) on physical activity by using the method of actigraphy.
Overall, we prospectively included 128 heart failure patients with severe TR (median age 79 years, 48% female) who were scheduled for TTVI. Patients were equipped with activity tracking devices for 1 week before TTVI, and again at 1-6 months and 1 year after TTVI. We compared continuous physical activity (CPA), defined as the mean number of steps/day with New York Heart Association class, quality of life assessments, and 6-min walk distance (all p <0.01). TTVI reduced TR to grade ≤2+ in 94% of patients. Median (interquartile range [IQR]) CPA at baseline was 3108 (1350-4959) steps/day, which increased by 31.4% to 3958 (1823-5657) steps/day at 1-6 months and 4080 (2293-6514) steps/day at 1 year after TTVI (p <0.001 for both comparisons). The impact of TTVI was significantly higher in advanced heart failure patients with low baseline activity (baseline CPA <1350 steps/day; 1-year CPA increase: +121.3%; p <0.001), when compared to moderate activity patients (baseline CPA 1350-4959 steps/day; 1-year CPA increase: +27.5%; p <0.01) or high activity patients (baseline CPA >4959 steps/day; 1-year CPA change: +2.6%; p = 0.39).
One-week actigraphy demonstrates durable improvement of physical activity after TTVI. Fragile chronic heart failure patients with very low baseline activity, as determined by actigraphy in this study, significantly benefit from transcatheter intervention and should not be excluded from TTVI.
三尖瓣反流(TR)与高死亡率、高发病率和身体活动能力降低有关。本研究旨在通过活动记录仪检查法来检测经导管三尖瓣介入治疗(TTVI)对身体活动的长期影响。
我们前瞻性纳入了 128 例因严重 TR 而计划行 TTVI 的心力衰竭患者(中位年龄 79 岁,48%为女性)。患者在 TTVI 前 1 周、TTVI 后 1-6 个月和 1 年佩戴活动跟踪设备。我们比较了连续身体活动(CPA),定义为每纽约心功能分级的平均步数/天,并比较了生活质量评估和 6 分钟步行距离(均 P<0.01)。TTVI 将 94%患者的 TR 减少至≤2+级。基线时(中位数(四分位距 [IQR])CPA 为 3108(1350-4959)步/天,TTVI 后 1-6 个月时增加至 3958(1823-5657)步/天,TTVI 后 1 年时增加至 4080(2293-6514)步/天(两者比较均 P<0.001)。在基线活动较低的晚期心力衰竭患者中,TTVI 的影响明显更高(基线 CPA<1350 步/天;1 年 CPA 增加:+121.3%;P<0.001),与中度活动患者(基线 CPA 1350-4959 步/天;1 年 CPA 增加:+27.5%;P<0.01)或高度活动患者(基线 CPA>4959 步/天;1 年 CPA 变化:+2.6%;P=0.39)相比。
为期 1 周的活动记录仪显示 TTVI 后身体活动持续改善。在这项研究中,通过活动记录仪确定的基线活动非常低的脆弱性慢性心力衰竭患者,从经导管干预中显著获益,不应被排除在 TTVI 之外。